ALK and non-small cell lung carcinoma: Lorlatinib is a potent and CNS-penetrant ALK and ROS1 inhibitor evaluated in a phase I/II clinical trial among patients with metastatic ROS1+ NSCLC (30% TKI-naïve and 70% TKI-pretreated).31 Among TKI-naïve patients, the ORR was 62% and mPFS 21 months.